Figure 6
Figure 6. Survival curves of patients with NPM1-mutated AML (MLD+ vs MLD−) from the MLL. (A) No significant differences in OS are observed between NPM1-mutated AML with (red line) and without (gray line) MLD (P = .370). (B) No significant differences in EFS are observed between NPM1-mutated AML with (red line) and without (gray line) MLD (P = .200). (C) No significant differences in OS are observed between normal karyotype NPM1-mutated AML with (red line) and without (gray line) MLD (P = .337). (D) No significant differences in EFS are observed between normal karyotype NPM1-mutated AML with (red line) and without (gray line) MLD (P = .137).

Survival curves of patients with NPM1-mutated AML (MLD+ vs MLD) from the MLL. (A) No significant differences in OS are observed between NPM1-mutated AML with (red line) and without (gray line) MLD (P = .370). (B) No significant differences in EFS are observed between NPM1-mutated AML with (red line) and without (gray line) MLD (P = .200). (C) No significant differences in OS are observed between normal karyotype NPM1-mutated AML with (red line) and without (gray line) MLD (P = .337). (D) No significant differences in EFS are observed between normal karyotype NPM1-mutated AML with (red line) and without (gray line) MLD (P = .137).

Close Modal

or Create an Account

Close Modal
Close Modal